MedPath

Improving Sleep for Healthy Hearts

Not Applicable
Completed
Conditions
Insomnia
Coronary Heart Disease
Registration Number
NCT02848859
Lead Sponsor
Brigham and Women's Hospital
Brief Summary

This is a pilot study randomizing patients with insomnia and coronary heart disease to either general sleep hygiene counseling and web-based cognitive behavioral therapy for insomnia versus general sleep hygiene counseling alone (followed by the cognitive behavioral therapy at a later date).

Detailed Description

For this pilot study, the investigators will recruit up to 30 participants with insomnia and coronary heart disease. Another 30 patients will be recruited from another institution. Patients will be screened with a modified version of the Insomnia Severity Index (ISI), a brief self-report instrument validated for identifying insomnia. The investigators will modify the ISI to include exclusionary criteria. The investigators will randomize participants to 6 weeks of access to web based cognitive behavioral therapy for insomnia (wCBT-I) using an internet based CBT-I program plus education provided through access to the Harvard Sleep Education web site (which provides general sleep education information only) compared to 6 weeks of access to the Harvard Sleep Education web site, followed by access to the web-CBT program (a wait list control group). The investigators will test the hypothesis that use of wCBT-I improves sleep quality and sleep duration as measured by sleep diaries and the ISI. A secondary goal of the study is to assess the recruitment yields, retention and adherence rates.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
34
Inclusion Criteria
  • meet criteria for at least mild insomnia based on the Insomnia Severity Index questionnaire results
  • have established coronary disease defined by: a) prior myocardial infarction or a coronary artery revascularization procedure; b) angiographically documented stenosis (>70%) of a major coronary artery; or c) prior ischemic stroke without major functional impairment.
  • minimum age of 18 years old.
Exclusion Criteria
  • no daily access to a computer with an internet connection
  • visual impairment preventing use of a computer
  • inability to read English
  • severe uncontrolled medical or psychiatric problems
  • heart failure with reduced ejection fraction <35%
  • high depressive symptoms (PHQ > 15)
  • drowsy driving
  • >3 days per week use of hypnotic medications
  • known untreated sleep disordered breathing, narcolepsy, or restless leg syndrome
  • shift-workers
  • prior exposure to CBT-I treatment
  • dialysis patient

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Change from baseline Insomnia Severity Index score at 6 weeksAt baseline, at 6 weeks, and in the treatment arm at 12 weeks.

It is a 7 item, validated questionnaire to determine severity of insomnia symptoms.

Secondary Outcome Measures
NameTimeMethod
Change in sleep duration from baseline to 6 weeksAt baseline, at 6 weeks, and in the treatment arm at 12 weeks.

The investigators will use sleep diaries that participants fill out for 1 week at baseline and at 6 weeks to compare sleep duration between arms as well as at 12 weeks in the treatment arm only to assess duration of treatment effect.

Change in mood assessed using the Patient Health Questionnaire-8 from baseline to 6 weeksAt baseline, at 6 weeks, and in the treatment arm at 12 weeks.

The investigators will use the Patient Health Questionnaire-8 to measure depressive symptoms

Change in sleepiness assessed using the Epworth Sleepiness Questionnaire from baseline to 6 weeksAt baseline, at 6 weeks, and in the treatment arm at 12 weeks.

The investigators will use the Epworth Sleepiness questionnaire to measure sleepiness.

Change in blood pressure from baseline to 6 weeksAt baseline and at 6 weeks

The investigators will measure seated blood pressure in triplicate and use the average of the latter two readings for blood pressure (taken at baseline and 6 week visits).

Change in heart rate from baseline to 6 weeksAt baseline and at 6 weeks

The investigators will measure seated heart rate in triplicate and use the average of the latter two readings for heart rate(taken at baseline and 6 week visits).

Change in Quality of life at baseline and 6 weeksAt baseline, at 6 weeks, and in the treatment arm at 12 weeks.

The investigators will measure this using the Duke Health Profile, another validated questionnaire to measure quality of life.

Trial Locations

Locations (1)

Brigham and Womens Hospital

🇺🇸

Boston, Massachusetts, United States

Brigham and Womens Hospital
🇺🇸Boston, Massachusetts, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.